Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ingram

Showing results (411-420 of 507) with videos related to

Pageof 51
Sort By:
Cancer|March 31, 2021
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasInga-Marie Schaefer, Meijun Z Lundberg, Elizabeth G Demicco, et al.
Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6 specific nanobody restricts M. tuberculosis growth in macrophagesTimothy A Bates, Mila Trank-Greene, Xammy Nguyenla, et al.
Journal of Comparative Physiology. B, Biochemical, Systemic, and Environmental Physiology|July 18, 2009
Comparing plasma and faecal measures of steroid hormones in Adelie penguins Pygoscelis adeliaeCalum Edward Ninnes, J R Waas, N Ling, et al.
Pain and Therapy|October 17, 2025
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical TrialsJohn R Ingram, Hideki Fujita, Alice B Gottlieb, et al.
Oncotarget|March 14, 2022
Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patientsEric R Molina, Letitia K Chim, Salah-Eddine Lamhamedi-Cherradi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2018
Anti-CTLA-4 therapy requires an Fc domain for efficacyJessica R Ingram, Olga S Blomberg, Mohammad Rashidian, et al.
Elife|May 28, 2024
ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts <i>M. tuberculosis</i> growth in macrophagesTimothy A Bates, Mila Trank-Greene, Xammy Nguyenla, et al.
Cancer Research|January 5, 2023
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real TimeTuyen Duong Thanh Nguyen, Yan Wang, Tuyen N Bui, et al.
Cancer Biology & Therapy|December 10, 2015
Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumorChristine M Kivlin, Kelsey L Watson, Ghadah A Al Sannaa, et al.
Pageof 51

Showing results (411-420 of 507) with videos related to

Sort By:
Pageof 51
Cancer|March 31, 2021
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasInga-Marie Schaefer, Meijun Z Lundberg, Elizabeth G Demicco, et al.
Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6 specific nanobody restricts M. tuberculosis growth in macrophagesTimothy A Bates, Mila Trank-Greene, Xammy Nguyenla, et al.
Journal of Comparative Physiology. B, Biochemical, Systemic, and Environmental Physiology|July 18, 2009
Comparing plasma and faecal measures of steroid hormones in Adelie penguins Pygoscelis adeliaeCalum Edward Ninnes, J R Waas, N Ling, et al.
Pain and Therapy|October 17, 2025
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical TrialsJohn R Ingram, Hideki Fujita, Alice B Gottlieb, et al.
Oncotarget|March 14, 2022
Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patientsEric R Molina, Letitia K Chim, Salah-Eddine Lamhamedi-Cherradi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2018
Anti-CTLA-4 therapy requires an Fc domain for efficacyJessica R Ingram, Olga S Blomberg, Mohammad Rashidian, et al.
Elife|May 28, 2024
ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts <i>M. tuberculosis</i> growth in macrophagesTimothy A Bates, Mila Trank-Greene, Xammy Nguyenla, et al.
Cancer Research|January 5, 2023
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real TimeTuyen Duong Thanh Nguyen, Yan Wang, Tuyen N Bui, et al.
Cancer Biology & Therapy|December 10, 2015
Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumorChristine M Kivlin, Kelsey L Watson, Ghadah A Al Sannaa, et al.
Pageof 51